GlaxoSmithKline plc

LON:GSK ISIN:GB0009252882

May 25, 2012

OVERVIEW | NEWS | MULTIMEDIA | RESEARCH

GlaxoSmithKline plc Company Summary

GlaxoSmithKline plc (LON:GSK) The Group's principal activities are manufacturing, developing and marketing of pharmaceutical and consumer health-related products. The Group operates in two industry segments: Pharmaceuticals, include prescription pharmaceuticals and vaccines, and Consumer Healthcare, include over-the-counter medicines, oral care and nutritional healthcare. Major markets include the USA, Japan, the UK, France, Germany and Italy. During 2001, the Group acquired Block Drug Co Inc and 50% of Shionogi. Pharmaceuticals accounted for 84% of 2001 revenues and Consumer healthcare, 16%.

COMPANY DATA

	Headquarters	980 Great West Road Brentford

		Middlesex, ENG TW8 9GS

		United Kingdom

	Telephone	+44-20-80475000

	Fax	+44-20-80477807

	Principal Sector	Health & Pharm General

	Principal Industry	Healthcare

	Homepage	www.gsk.com

Key Developments: GlaxoSmithKline plc

	Dart Energy Limited (ASX:DTE) Executive And Management Team In-Place To Deliver Growth OCT 13, 2010 13:00 - Article Views: 3,212 Following the Demerger of Dart Energy Limited (ASX:DTE) from Arrow Energy Limited (ASX:AOE) (PINK:ARWEF) and the subsequent establishment of Dart as an independent ASX-listed company, the Board has been seeking to build out the executive and management team of Dart.

	Asian Markets Overview of February 22 FEB 22, 2010 13:30 - Article Views: 3,873 Asian shares Monday are expected to be buoyed after Wall Street delivered its best week of the year. China's Shanghai bourse will open today after a long holiday for the Lunar New Year. The Hong Kong and Tokyo stocks lost more than 2 percent Friday on U.S. Federal Reserve's decision to raise its discount rate. The discount rate hike also sent commodities prices lower and hit resources shares in the region.

	Biota Holdings Limited (ASX:BTA) Notes Important Initiatives By GSK to Respond to the New Influenza A (H1N1) Strain MAY 4, 2009 09:25 - Article Views: 4,345 Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) notes that GlaxoSmithKline (GSK) has announced important initiatives to assist governments and health authorities around the world to respond to the emergence of the new influenza A (H1N1) strain (previously referred to as Swine Flu).

	Biota Holdings Limited (ASX:BTA) Announced Thier Relenza Royalty for March 2009 Quarter At A$32.3 Million APR 23, 2009 10:52 - Article Views: 5,172 Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today announced that it had received notification from GlaxoSmithKline (LON:GSK) that Relenza sales were A$462 million and indicative royalties were A$32.3 million, for the three months ended 31 March 2009.

	Biota Holdings Limited (ASX:BTA) Revised Relenza Royalty For December 2008 Quarter FEB 13, 2009 11:45 - Article Views: 2,879 Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today reported that it had received revised advice from GlaxoSmithKline (GSK) regarding Relenza sales for the December 2008 quarter. The revised sales were A$27.1 million (US$20.8 million) and indicative royalties were A$1.9 million (US$1.46 million).

	Biota Holdings Limited (ASX:BTA) GSK Imports Additional Relenza To Japan FEB 11, 2009 10:27 - Article Views: 3,473 Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today announced that GlaxoSmithKline (GSK) has advised of the current Relenza supply situation in respect to the key market of Japan.

	Biota Holdings Limited (ASX:BTA) Relenza Royalty For December 2008 Quarter FEB 6, 2009 10:04 - Article Views: 2,712 Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today announced that it had received written notification from GlaxoSmithKline (GSK) that Relenza sales were $20.8 million and indicative royalties were $1.46 million, for the three months ended 31 December 2008.

	Biota Holdings Limited (ASX:BTA) UK GOVERNMENT ORDERS 10.6 MILLION COURSES OF RELENZA JAN 30, 2009 10:41 - Article Views: 2,408 Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today announced that GlaxoSmithKline (GSK) has been awarded a significant contract by the UK Department of Health for 10.6 million treatment courses of RelenzaTM (zanamivir).

	Kinaxo Biotechnologies Awarded Grant To Expand Applications For Its Chemical Proteomics Platform JULY 24, 2008 18:03 - Article Views: 1,361 Kinaxo Biotechnologies GmbH Martinsried, Germany, 24thJuly 2008.

	Billerud Second Quarter Results 2008 JULY 24, 2008 16:03 - Article Views: 1,122 ZoomVision Second quarter results 2008 Invitation to press and telephone conference